AtriCure (ATRC) Receiving Somewhat Positive Press Coverage, Study Shows

Media coverage about AtriCure (NASDAQ:ATRC) has been trending somewhat positive recently, according to AlphaOne Sentiment. The research group, a unit of Accern, identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AtriCure earned a daily sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also assigned media headlines about the medical device company an impact score of 0 out of 100, indicating that recent press coverage is extremely unlikely to have an impact on the stock’s share price in the immediate future.

Here are some of the media headlines that may have impacted AlphaOne’s rankings:

Insider Buying and Selling by Quarter for AtriCure (NASDAQ:ATRC)

A number of analysts recently commented on the company. Leerink Swann reaffirmed an “outperform” rating and set a $26.00 price objective on shares of AtriCure in a research note on Friday. TheStreet raised AtriCure from a “d+” rating to a “c-” rating in a research note on Monday, May 15th. ValuEngine raised AtriCure from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $26.00 price objective on shares of AtriCure in a research note on Tuesday, May 30th. Finally, Zacks Investment Research raised AtriCure from a “hold” rating to a “buy” rating and set a $26.00 price objective on the stock in a research note on Tuesday, May 9th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $23.56.

Shares of AtriCure (NASDAQ:ATRC) traded down 0.36% during mid-day trading on Friday, reaching $21.84. The company’s stock had a trading volume of 283,662 shares. AtriCure has a 52-week low of $13.45 and a 52-week high of $23.95. The firm’s 50 day moving average is $21.44 and its 200-day moving average is $18.97. The company’s market capitalization is $741.38 million.

AtriCure (NASDAQ:ATRC) last issued its quarterly earnings results on Thursday, May 4th. The medical device company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.01. AtriCure had a negative return on equity of 19.89% and a negative net margin of 21.07%. The business had revenue of $41.30 million for the quarter, compared to the consensus estimate of $40.25 million. During the same quarter in the previous year, the company posted ($0.31) earnings per share. AtriCure’s revenue for the quarter was up 15.0% compared to the same quarter last year. Analysts forecast that AtriCure will post ($0.96) EPS for the current year.

In other news, Director Elizabeth D. Krell sold 10,000 shares of AtriCure stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total transaction of $214,400.00. Following the transaction, the director now owns 24,162 shares in the company, valued at $518,033.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.00% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was originally reported by sleekmoney and is owned by of sleekmoney. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at

About AtriCure

AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *